AU5876899A - Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases - Google Patents
Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseasesInfo
- Publication number
- AU5876899A AU5876899A AU58768/99A AU5876899A AU5876899A AU 5876899 A AU5876899 A AU 5876899A AU 58768/99 A AU58768/99 A AU 58768/99A AU 5876899 A AU5876899 A AU 5876899A AU 5876899 A AU5876899 A AU 5876899A
- Authority
- AU
- Australia
- Prior art keywords
- polymorphisms
- diagnosis
- integrin
- treatment
- mediated diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9820339.1A GB9820339D0 (en) | 1998-09-19 | 1998-09-19 | Chemical compounds |
| GB9820339 | 1998-09-19 | ||
| GBGB9824506.1A GB9824506D0 (en) | 1998-11-10 | 1998-11-10 | Chemical compounds |
| GB9824506 | 1998-11-10 | ||
| PCT/GB1999/003071 WO2000017394A1 (en) | 1998-09-19 | 1999-09-15 | Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5876899A true AU5876899A (en) | 2000-04-10 |
Family
ID=26314385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU58768/99A Abandoned AU5876899A (en) | 1998-09-19 | 1999-09-15 | Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1112381A1 (en) |
| JP (1) | JP2002526091A (en) |
| AU (1) | AU5876899A (en) |
| WO (1) | WO2000017394A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10019058A1 (en) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Designing primers and probes for analyzing diseases associated with cytosine methylation state e.g. arthritis, cancer, aging, arteriosclerosis comprising fragments of chemically modified genes associated with cell cycle |
| ES2325807T3 (en) | 2001-03-30 | 2009-09-18 | Shunichi Shiozawa | GENOMIC DNA PARTICIPATING IN THE Rheumatoid ARTHRITIS, PROCEDURE FOR ITS DIAGNOSIS, PROCEDURE FOR ESTIMATING YOUR APPEARANCE AND DIAGNOSTIC KIT FOR DETECTION. |
| WO2008039941A2 (en) | 2006-09-27 | 2008-04-03 | The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services | Scgb3a2 as a growth factor and anti-apoptotic agent |
| GB2466025A (en) * | 2008-12-08 | 2010-06-09 | Univ Francois Rabelais De Tour | C3/ITGAM polymorphisms and cancer prognosis |
| WO2013001819A1 (en) | 2011-06-30 | 2013-01-03 | 株式会社免疫生物研究所 | SOLUBLE INTEGRIN α4 MUTANT |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK162890D0 (en) * | 1990-07-06 | 1990-07-06 | Novo Nordisk As | POLYPEPTIDE |
| WO1997040462A2 (en) * | 1996-04-19 | 1997-10-30 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
-
1999
- 1999-09-15 AU AU58768/99A patent/AU5876899A/en not_active Abandoned
- 1999-09-15 EP EP99946354A patent/EP1112381A1/en not_active Withdrawn
- 1999-09-15 JP JP2000574293A patent/JP2002526091A/en active Pending
- 1999-09-15 WO PCT/GB1999/003071 patent/WO2000017394A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1112381A1 (en) | 2001-07-04 |
| JP2002526091A (en) | 2002-08-20 |
| WO2000017394A1 (en) | 2000-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002255248A1 (en) | Diagnosis, treatment and research of mental disorders | |
| GB9903841D0 (en) | Diagnosis and treatment of cancer | |
| HK1033278A1 (en) | Pharmaceutical preparation for use in anti-asthma therapy. | |
| IL164839A0 (en) | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
| AU7896100A (en) | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance | |
| AU5215300A (en) | Dental treatment area | |
| ZA97741B (en) | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders. | |
| AU7748200A (en) | Hypoxia-related human genes, proteins, and uses thereof | |
| AU6425800A (en) | Agents for the diagnosis, prognosis and treatment of malignant diseases | |
| HUP0201997A2 (en) | Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications | |
| AU6583700A (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| AU3760400A (en) | Methods and reagents for the diagnosis and treatment of multiple sclerosis | |
| EP0676200A3 (en) | Use of eliprodil and of its enantiomers in the preparation of medicaments for the treatment of peripheral neuropathies and or central neurodegenerative diseases. | |
| AU2729400A (en) | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease | |
| AU1101901A (en) | Human fgf-20 gene and gene expression products | |
| AU3593599A (en) | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
| AU5876899A (en) | Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases | |
| AU4654500A (en) | Prevention, diagnosis and treatment of lyme disease | |
| AU5876399A (en) | Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases | |
| AU1774299A (en) | Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment | |
| AU2003245858A1 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
| AU5875599A (en) | Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases | |
| AU5618700A (en) | Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer | |
| AU2001240820A1 (en) | Proteins, genes and their use for diagnosis and treatment of vascular dementia | |
| NZ513739A (en) | Cloning of cDNA of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |